Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

American journal of clinical and experimental urology

Armstrong CM, Gao AC.
PMID: 26309896
Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015.

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for CRPC include systemic drugs (docetaxel and cabazitaxel) and agents that target androgen signaling, including enzalutamide and abiraterone. While up...

Cite
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015;3(2):64-76
Armstrong, C. M., & Gao, A. C. (2015). Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. American journal of clinical and experimental urology, 3(2), 64-76.
Armstrong, Cameron M, and Gao, Allen C. "Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies." American journal of clinical and experimental urology vol. 3,2 (2015): 64-76.
Armstrong CM, Gao AC. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol. 2015 Aug 08;3(2):64-76. eCollection 2015. PMID: 26309896; PMCID: PMC4539108.
Copy Download .nbib Format: NLM
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.

Genes & cancer

Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC.
PMID: 21779488
Genes Cancer. 2011 Feb;2(2):151-9. doi: 10.1177/1947601911409744.

Androgen receptor (AR) signaling not only plays a pivotal role in the development of androgen-dependent prostate cancer but is also important in the growth and survival of castration-resistant prostate cancer (CRPC). The first line of treatment of androgen-dependent prostate...

Cite
Liu C, Nadiminty N, Tummala R, et al. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2011;2(2):151-9doi: 10.1177/1947601911409744.
Liu, C., Nadiminty, N., Tummala, R., Chun, J. Y., Lou, W., Zhu, Y., Sun, M., Evans, C. P., Zhou, Q., & Gao, A. C. (2011). Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes & cancer, 2(2), 151-9. https://doi.org/10.1177/1947601911409744
Liu, Chengfei, et al. "Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer." Genes & cancer vol. 2,2 (2011): 151-9. doi: https://doi.org/10.1177/1947601911409744
Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2011 Feb;2(2):151-9. doi: 10.1177/1947601911409744. PMID: 21779488; PMCID: PMC3111248.
Copy Download .nbib Format: NLM
Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

Asian journal of urology

Armstrong CM, Gao AC.
PMID: 28642838
Asian J Urol. 2016 Oct;3(4):185-194. doi: 10.1016/j.ajur.2016.08.001. Epub 2016 Aug 22.

The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is estimated...

Cite
Armstrong CM, Gao AC. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian J Urol. 2016;3(4):185-194doi: 10.1016/j.ajur.2016.08.001.
Armstrong, C. M., & Gao, A. C. (2016). Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian journal of urology, 3(4), 185-194. https://doi.org/10.1016/j.ajur.2016.08.001
Armstrong, Cameron M, and Gao, Allen C. "Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer." Asian journal of urology vol. 3,4 (2016): 185-194. doi: https://doi.org/10.1016/j.ajur.2016.08.001
Armstrong CM, Gao AC. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian J Urol. 2016 Oct;3(4):185-194. doi: 10.1016/j.ajur.2016.08.001. Epub 2016 Aug 22. PMID: 28642838; PMCID: PMC5477778.
Copy Download .nbib Format: NLM
Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth.

Genes & cancer

Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC.
PMID: 21442031
Genes Cancer. 2010 Aug;1(8):868-76. doi: 10.1177/1947601910383416.

Elevated interleukin-6 (IL-6), a major mediator of the inflammatory response, has been implicated in androgen receptor (AR) activation, cellular growth and differentiation, plays important roles in the development and progression of prostate cancer, and is a potential target in...

Cite
Chun JY, Tummala R, Nadiminty N, et al. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer. 2010;1(8):868-76doi: 10.1177/1947601910383416.
Chun, J. Y., Tummala, R., Nadiminty, N., Lou, W., Liu, C., Yang, J., Evans, C. P., Zhou, Q., & Gao, A. C. (2010). Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes & cancer, 1(8), 868-76. https://doi.org/10.1177/1947601910383416
Chun, Jae Yeon, et al. "Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth." Genes & cancer vol. 1,8 (2010): 868-76. doi: https://doi.org/10.1177/1947601910383416
Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer. 2010 Aug;1(8):868-76. doi: 10.1177/1947601910383416. PMID: 21442031; PMCID: PMC3063649.
Copy Download .nbib Format: NLM
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression.

Genes & cancer

Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC.
PMID: 21318089
Genes Cancer. 2010 Mar;1(3):283-92. doi: 10.1177/1947601910368849.

Prostate cancer is a frequently occurring disease and is the second leading cause of cancer-related deaths of men in the United States. Current treatments have proved inadequate in curing or controlling prostate cancer, and a search for agents for...

Cite
Sun M, Lou W, Chun JY, et al. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer. 2010;1(3):283-92doi: 10.1177/1947601910368849.
Sun, M., Lou, W., Chun, J. Y., Cho, D. S., Nadiminty, N., Evans, C. P., Chen, J., Yue, J., Zhou, Q., & Gao, A. C. (2010). Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes & cancer, 1(3), 283-92. https://doi.org/10.1177/1947601910368849
Sun, Meng, et al. "Sanguinarine suppresses prostate tumor growth and inhibits survivin expression." Genes & cancer vol. 1,3 (2010): 283-92. doi: https://doi.org/10.1177/1947601910368849
Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer. 2010 Mar;1(3):283-92. doi: 10.1177/1947601910368849. PMID: 21318089; PMCID: PMC3036540.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries